6 insiders reported 10 Form 4 transactions for Arbutus Biopharma Corp (ABUS) over the past 18 months (most recent 2026-02-02). Recent activity: Androski Lindsay (President and CEO) Buy 28,000 shares, Nguyen Tuan (Chief Financial Officer) Buy 73,500 shares, McElhaugh Michael J. (Interim President & CEO) Buy 177,000 shares, Naftzger J. Christopher (General Counsel and CCO) Buy 54,300 shares, Sims Karen (Chief Medical Officer) Buy 49,300 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-02 | Androski Lindsay | President and CEO | Buy | 28,000 | $0 |
| 2026-02-02 | Nguyen Tuan | Chief Financial Officer | Buy | 73,500 | $0 |
| 2025-02-19 | McElhaugh Michael J. | Interim President & CEO | Buy | 177,000 | $0 |
| 2025-02-19 | Naftzger J. Christopher | General Counsel and CCO | Buy | 54,300 | $0 |
| 2025-02-19 | Sims Karen | Chief Medical Officer | Buy | 49,300 | $0 |
| 2025-02-19 | HASTINGS DAVID C | Chief Financial Officer | Buy | 90,100 | $0 |
| 2025-02-05 | HASTINGS DAVID C | Chief Financial Officer | Sell | 22,183 | $72,760 |
| 2025-02-05 | McElhaugh Michael J. | Interim President & CEO | Sell | 23,790 | $78,031 |
| 2025-02-05 | Sims Karen | Chief Medical Officer | Sell | 19,348 | $63,461 |
| 2025-02-05 | Naftzger J. Christopher | General Counsel and CCO | Sell | 11,333 | $37,172 |
Source: SEC Form 4 filings · as of 2026-02-02